These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19875584)

  • 1. Triglycerides and HDL cholesterol: stars or second leads in diabetes?
    Bitzur R; Cohen H; Kamari Y; Shaish A; Harats D
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S373-7. PubMed ID: 19875584
    [No Abstract]   [Full Text] [Related]  

  • 2. A case report of a diabetic woman with very low HDL cholesterol.
    Chaychi L; Kinlaw WB; Asztalos BF; Schaefer EJ
    J Clin Lipidol; 2010; 4(2):133-5. PubMed ID: 21122641
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Bilz S
    Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing diabetic dyslipidemia: beyond statin therapy.
    Neeli H; Gadi R; Rader DJ
    Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of triglycerides in atherosclerosis.
    Talayero BG; Sacks FM
    Curr Cardiol Rep; 2011 Dec; 13(6):544-52. PubMed ID: 21968696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triglyceride to high-density lipoprotein cholesterol ratio and risk of atherosclerotic cardiovascular disease in a Chinese population.
    Zhou L; Mai J; Li Y; Guo M; Wu Y; Gao X; Wu Y; Liu X; Zhao L
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1706-1713. PubMed ID: 32811737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
    Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study.
    Orsi E; Penno G; Solini A; Bonora E; Fondelli C; Trevisan R; Vedovato M; Cavalot F; Morano S; Baroni MG; Nicolucci A; Pugliese G;
    Cardiovasc Diabetol; 2021 Jan; 20(1):28. PubMed ID: 33516215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol-to-apolipoprotein B ratio as a potential indicator of LDL particle size and plasma atherogenicity in type 2 diabetes.
    Viktorinova A; Malickova D; Svitekova K; Choudhury S; Krizko M
    Diabetes Res Clin Pract; 2021 Jun; 176():108858. PubMed ID: 34015391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.
    Bruckert E; Baccara-Dinet M; Eschwege E
    Diabet Med; 2007 Apr; 24(4):388-91. PubMed ID: 17335463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
    Falko JM; Moser RJ; Meis SB; Caulin-Glaser T
    Curr Diabetes Rev; 2005 May; 1(2):127-35. PubMed ID: 18220588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?].
    Broedl UC; Lehrke M; Parhofer KG
    MMW Fortschr Med; 2008 Jun; 150(25):41-3. PubMed ID: 18705054
    [No Abstract]   [Full Text] [Related]  

  • 15. The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
    Manoria PC; Chopra HK; Parashar SK; Dutta AL; Pinto B; Mullasari A; Prajapati S
    Indian Heart J; 2013 Dec; 65(6):683-90. PubMed ID: 24407538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low HDL cholesterol is associated with the risk of stroke in elderly diabetic individuals: changes in the risk for atherosclerotic diseases at various ages.
    Hayashi T; Kawashima S; Itoh H; Yamada N; Sone H; Watanabe H; Hattori Y; Ohrui T; Yokote K; Nomura H; Umegaki H; Iguchi A;
    Diabetes Care; 2009 Jul; 32(7):1221-3. PubMed ID: 19509009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
    Savinova OV; Fillaus K; Harris WS; Shearer GC
    Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.